Treatment of Melanoma by Nano-conjugate-Delivered Wee1 siRNA (2021)
Sequence: RRRRRRRR–cRGD
| Experiment Id | EXP002406 |
|---|---|
| Paper | Treatment of Melanoma by Nano-conjugate-Delivered Wee1 siRNA |
| Peptide | R8–cRGD CPP |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | 50–60 µg RRCPP per dose |
| Rna Concentration | 10–12 µg siRNA per dose |
| Mixing Ratio | RRCPP:siRNA complex |
| Formulation Format | polymeric nano-conjugate (RRCPP/siRNA) |
| Formulation Components | LMW PEI (1.8 kDa), cholesterol, PEG, R8–cRGD peptide |
| Size Nm | 110.00 |
| Zeta Mv | 45.00 |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | B16 melanoma xenograft and lung metastasis mouse models |
| Administration Route | intratumoral (subcutaneous) or intravenous |
| Output Type | tumor growth inhibition, metastasis reduction |
| Output Value | ~85% tumor growth inhibition; ~66% lung metastasis inhibition |
| Output Units | |
| Output Notes | Significant tumor regression, Wee1 knockdown, apoptosis (TUNEL), survival benefit. |
| Toxicity Notes | No significant organ toxicity (H&E histology) |
| Curation Notes |